A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (Dox) with or without olaratumab (IMC-3G3), a human anti-platelet-derived growth factor a (pdgfra) monoclonal antibody, in advanced soft tissue sarcoma (sts) Meeting Abstract
| Authors: | Tap, W.; Jones, R. L.; Chmelowski, B.; Elias, A. A.; Adkins, D.; Van Tine, B. A.; Agulnik, M.; Cooney, M.; Livingston, M. B.; Pennock, G.; Quin, A.; Shahir, A.; Ilaria, R.; Conti, I.; Schwartz, G. K. |
| Abstract Title: | A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (Dox) with or without olaratumab (IMC-3G3), a human anti-platelet-derived growth factor a (pdgfra) monoclonal antibody, in advanced soft tissue sarcoma (sts) |
| Meeting Title: | 32. Deutscher Krebskongress Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ (DKK 2016) |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 39 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2016 Feb 24-27 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2016-02-01 |
| Start Page: | 174 |
| Language: | English |
| ACCESSION: | WOS:000371353700565 |
| PROVIDER: | wos |
| PUBMED: | 26905290 |
| DOI: | 10.1159/000444354 |
| Notes: | Meeting Abstract: ID0574 -- [32nd German Cancer Congress – Cancer Medicine Today: Preventive, Personalized, Precise and Participative] -- Source: Wos |
